CJC-1295 with DAC is a long-acting Growth Hormone–Releasing Hormone (GHRH) analogue designed to stimulate sustained, physiologic growth hormone (GH) release. The addition of the Drug Affinity Complex (DAC) allows the peptide to bind to albumin in the bloodstream, significantly extending its half-life and reducing dosing frequency.
$39.00
For laboratory research use only. Not for human or animal use or consumption. Not a drug, food, dietary supplement, or cosmetic. Not approved by the FDA for any medical use.
This modified version of GHRH (1–29) promotes prolonged GH secretion by acting on pituitary somatotroph cells, resulting in sustained increases in endogenous GH and downstream IGF-1 levels. Due to its extended duration in circulation—approximately 6–8 days—CJC-1295 with DAC supports long-term metabolic efficiency, tissue regeneration, and recovery.
Dosage Guidelines (Research Use):
A common research protocol consists of 100–300 mcg administered in the morning, preferably before workouts and in a fasted state. The total weekly dose may be delivered as a single injection or divided into multiple administrations based on research design and individual response.
Cycle Length:
Typical cycles last 8–10 weeks, followed by a recommended off-cycle of 4–8 weeks to maintain responsiveness.
Stacking Recommendation:
CJC-1295 with DAC is often stacked with Ipamorelin to enhance growth hormone pulse amplitude and overall effectiveness.
Important Notes:
Carbohydrates and dietary fats may blunt growth hormone release. For optimal results, administration is recommended 30 minutes before eating or at least 2 hours after meals.
Useful Information:
Class: Long-acting Growth Hormone–Releasing Hormone (GHRH) analogue
Mechanism: Albumin binding via DAC extends half-life and supports sustained GH and IGF-1 elevation
Category: Growth Hormone Peptides
All products are intended for laboratory research use only and are not for human or animal consumption or medical use.
Reviews
There are no reviews yet.